SEC Form 4 · accession 0001104659-15-042497
Vitae Pharmaceuticals, Inc · VTAE
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Donald J Hayden Jr.
Director
Period of report
May 28, 2015
Accepted (ET)
Jun 1, 2015 · 4:40 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001157602
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F1 | $12.43 | May 28, 2015 | A | 10,000 | A | — | May 27, 2025 | Common Stock | 10,000 | 10,000 | D |
Explanation of responses
- F1The option will vest in equal quarterly installments over one year of service following the grant date.